Finance

Stocks for Your Case: Expeditors International of Washington, Inc. (NASDAQ:EXPD) – Abbott Laboratories (NYSE:ABT)

Expeditors International of Washington, Inc. (NASDAQ:EXPD)

Expeditors International of Washington, Inc. is a leading provider of global logistics solutions. A Fortune 500 service-based logistics company provides, it offers its customers a seamless international network supporting the movement and strategic positioning of goods. The company’s services include the consolidation or forwarding of air and ocean freight. And customized logistics solutions. In each U.S. office, and in many overseas offices, the company acts as a customs broker. The company also provides additional services including distribution management, vendor consolidation, cargo insurance, and purchase order management. Expeditors International generates highly optimized and customized supply chain solutions for their clients with unified technology systems integrated through a global network of 331 locations in 109 countries on six continents. The company also provides additional services including distribution management, vendor consolidation, cargo insurance, and purchase order management.

Expeditors International of Washington, Inc. (NASDAQ:EXPD)’s Financial Overview

Expeditors International of Washington, Inc. (NASDAQ) surged 2.58% yesterday to close its trading session at $68.09. The company has 1 year Price Target of $73.21. Expeditors International of Washington, Inc. has 52-Week high of $78.16 and 52-Week Low of $59.1. The stock touched its 52-Week High on 78.16 and 52-Week Low on 59.10. The stock traded with the volume of 1.27 Million shares yesterday. The firm shows the market capitalization of $12.06 Billion.

Expeditors International of Washington, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.92/share against the analyst consensus estimate of $0.79/share. The difference between the actual and expected EPS is $0.13 a share with a surprise factor of 16.5%.

The firm is trading with SMA20 of -3.03 Percent, SMA50 of -3.04 Percent and SMA200 of -3.94 percent. Expeditors International of Washington, Inc. has P/S value of 1.55 while its P/B value stands at 6.04. Similarly, the company has Return on Assets of 18.9 percent, Return on Equity of 31 percent and Return on Investment of 21.7 Percent. The company shows Gross Margin and Operating Margin of 32.9 percent and 10 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 3.1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 13 analysts offering 12-month price forecasts for Expeditors International of Washington Inc have a median target of 71.00, with a high estimate of 78.00 and a low estimate of 57.00. The median estimate represents a +4.27% increase from the last price of 68.09.

Expeditors International of Washington, Inc. is estimated to report earnings on 02/19/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.84. The reported EPS for the same quarter last year was $0.71.

Abbott Laboratories (NYSE:ABT)

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

Abbott Laboratories (NYSE:ABT)’s Financial Outlook

The 20 analysts offering 12-month price forecasts for Abbott Laboratories have a median target of 80.00, with a high estimate of 86.00 and a low estimate of 60.00. The median estimate represents a +10.60% increase from the last price of 72.33.

Abbott Laboratories is expected* to report earnings on 01/23/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 10 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.81. The reported EPS for the same quarter last year was $0.74.

According to Zacks Investment Research, Abbott Laboratories has a Consensus Recommendation of 1.33. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 1.74% and closed its last trading session at $72.33. The company has the market capitalization of $130.35 Billion. The stock has 52-week high of $74.92 and 52-Week low of $55.58. The firm touched its 52-Week high on 74.92 and 52-Week low on 55.58. The company has volume of 5.15 Million shares. The company has a total of 1.8 Billion shares outstanding.

Abbott Laboratories (NYSE) in the last quarter reported its actual EPS of $0.75/share where the analyst estimated EPS was $0.75/share. The difference between the actual and Estimated EPS is $0. This shows a surprise factor of 0 percent.

The company has YTD performance of 26.74 percent. Beta for Abbott Laboratories stands at 1.26 while its ATR (average true range) is 2.06. The company has Weekly Volatility of 3.32%% and Monthly Volatility of 2.79%%.

Abbott Laboratories has distance from 20-day Simple Moving Average (SMA20) of 2.29%, Distance from 50-Day Simple Moving Average of 3.24 percent and Distance from 200-Day Simple Moving Average of 10.89%.

The Company currently has ROA (Return on Assets) of 1.2 percent, Return on Equity (ROE) of 2.9 Percent and Return on Investment (ROI) of 2.2% with Gross margin of 58 percent and Operating & Profit margin of 10.2% and 2.9% respectively.